Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA
Melbourne (Australia) and Liège (Belgium) – 25 January 2022. Telix announces that Raphaël Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa (EMEA).
Telix is pleased to announce that Raphaël Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa (EMEA).
Raphaël joins Telix with more than 20 years of pharmaceutical industry experience in a variety of roles, including in finance, business development, marketing and sales, as well as general management in Europe, Latin America and Asia. Prior to joining Telix, Raphaël worked at Advanced Accelerator Applications (AAA), a Novartis Company, for six years, most recently in the role of Asia-Pacific Cluster Head, setting up the radioligand therapy operations in the region. Earlier in his career, Raphaël worked at IPSEN, where he held several management positions, lastly serving as VP Global Marketing for Endo-Oncology.
On joining Telix Raphaël stated, “Molecularly targeted radiation is progressively becoming a mainstream oncology solution. In a very short period of time, Telix has emerged a major player in this field, thanks to a very talented team, an entrepreneurial and purpose-driven mindset and a strong and diverse pipeline. I am thrilled to be joining that team as the Company transitions to commercialisation, and very much looking forward to making our innovative products available in the EMEA region in order to help cancer patients live longer, better quality lives.”
Telix EMEA President, Richard Valeix added, “It is a great pleasure to welcome Raphaël to the team at this important moment in the Company’s evolution. With deep radiopharmaceutical experience and commercial know-how, Raphaël is well positioned to lead Telix’s EMEA operations in support of our purpose to help people with cancer and rare diseases live longer, better quality lives.”
To read the full media release please click here.
To return to Telix’s home page please click here.